BTC$62,533.00-3.27%
ETH$1,660.02-4.47%
USDT$0.9988-0.01%
BNB$574.70-3.18%
USDC$0.9998+0.00%
XRP$1.10-3.16%
SOL$68.97-5.07%
TRX$0.3301-0.45%
FIGR_HELOC$1.04+0.35%
HYPE$62.57-7.36%
DOGE$0.079-5.01%
USDS$0.99960.00%
RAIN$0.0157+4.11%
LEO$9.54-0.17%
ZEC$417.90-7.62%
XLM$0.1932-6.36%
BTC$62,533.00-3.27%
ETH$1,660.02-4.47%
USDT$0.9988-0.01%
BNB$574.70-3.18%
USDC$0.9998+0.00%
XRP$1.10-3.16%
SOL$68.97-5.07%
TRX$0.3301-0.45%
FIGR_HELOC$1.04+0.35%
HYPE$62.57-7.36%
DOGE$0.079-5.01%
USDS$0.99960.00%
RAIN$0.0157+4.11%
LEO$9.54-0.17%
ZEC$417.90-7.62%
XLM$0.1932-6.36%
Eli Lilly & Co. reported its results for the third quarter of 2024, with revenue up 20% y/y but failing to meet market expectations.
Eli Lilly's stock surged on news of its diabetes drug while Tesla saw a modest gain following news of reduced EU tariffs. Meanwhile, BAC declined after…
Eli Lilly (LLY) surged on strong Q2 earnings driven by GLP-1 drug sales, while Warner Bros. Discovery (WBD) plummeted following a massive $11.2 billion impairment charge.
Eli Lilly and Company (NYSE: LLY) has reported a strong financial performance for the second quarter of 2024, with revenue reaching $11.30 billion.
Eli Lilly's weight loss drug tirzepatide has received approval from Chinese regulators, intensifying competition with Novo Nordisk.
In today's market, Carnival Corporation and Eli Lilly are seeing significant stock gains due to strong earnings and a groundbreaking AI partnership, respectively. Meanwhile, Dollar Tree…
Eli Lilly and Company (NYSE: LLY) exceeded fourth-quarter expectations with a revenue increase to $9.35 billion, driven by strong sales of new products.